Group 1 - The core viewpoint highlights the significant growth and performance of the Kexin Pharmaceutical ETF managed by Jiashi, with a notable increase in trading volume and fund size [2] - As of July 9, the Kexin Pharmaceutical ETF achieved a daily average trading volume of 34.95 million yuan over the past month, ranking first among comparable funds [2] - The fund's size increased by 16.76 million yuan in the past two weeks, also ranking first among comparable funds [2] - The ETF saw a total inflow of 12.84 million yuan over the last ten trading days, indicating strong investor interest [2] - The net value of the Kexin Pharmaceutical ETF rose by 36.83% over the past year, showcasing its strong performance [2] Group 2 - The top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index account for 50.3% of the index, with leading companies including United Imaging Healthcare and BeiGene [2][4] - On July 9, Shanghai Pharmaceuticals announced an expected net profit of 4.45 billion yuan for the first half of 2025, representing a year-on-year increase of approximately 52% [4] Group 3 - Short-term market expectations for overseas transactions in innovative drugs are high, leading to a continuous rise in valuations [5] - China's innovative drug research and development capabilities are competitive globally, and the trend of innovative drugs going overseas is expected to persist [5] - The commercial health insurance sector in China is anticipated to see significant growth in premium income and payout rates, becoming an important source of funding for innovative drugs [5]

Group 1 - The medical innovation ETF (516820) has seen a 0.57% increase, with significant gains in constituent stocks such as Haizhi Science (10.00%) and Kanghong Pharmaceutical (2.04%) [1] - Haizhi Science has received IND approvals for multiple innovative drugs, indicating a positive trend in the innovative drug sector [1] - CITIC Securities points out that the innovative drug industry is experiencing a favorable policy environment, with domestic companies gradually increasing their performance, signaling an upcoming harvest period [1] Group 2 - The total healthcare expenditure in China is expected to achieve stable and sustainable growth, with a focus on identifying sub-sectors that can outpace the average industry growth rate [2] - Key themes for long-term growth in the pharmaceutical industry include innovation, consumption upgrades, and high-end manufacturing [2] - The medical innovation ETF (516820) is positioned to capture opportunities in quality leading companies that may have been undervalued [2]

二、药品其他相关情况 1 证券代码：688578 证券简称：艾力斯 公告编号：2025-015 上海艾力斯医药科技股份有限公司 自愿披露关于甲磺酸伏美替尼片 EGFR 20 外显子插入 突变 NSCLC 二线治疗适应症拟纳入优先审评程序的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上海艾力斯医药科技股份有限公司（以下简称"公司"）产品甲磺酸伏美替 尼片（以下简称"伏美替尼"）拟用于"既往经含铂化疗治疗时或治疗后出现疾 病进展，或不耐受含铂化疗，并且经检测确认存在表皮生长因子受体（EGFR） 20 外显子插入突变的局部晚期或转移性 NSCLC 成人患者的治疗"的药品上市许 可申请近日被国家药品监督管理局药品审评中心（CDE）纳入拟优先审评品种公 示名单，公示期为 2025 年 7 月 8 日至 2025 年 7 月 15 日。 由于药品优先审评程序认定在公示期存在被提出异议的风险，且药品新增适 应症上市申请尚需经过审评、药品临床试验现场检查和审批等环节，药品注册批 件取得时间和结果均具有不确定性。敬 ...

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [2] Core Insights - The pharmaceutical and biotechnology industry index increased by 5.30%, outperforming the CSI 300 index which rose by 3.52% during the reporting period [3][14] - The PE ratio (TTM, excluding negative values) for the pharmaceutical and biotechnology industry as of July 4, 2025, is 28.52x, up from 27.28x in the previous period, indicating an upward trend in valuation [3][19] - Notable sub-industries include "Other Biological Products" and "Medical R&D Outsourcing," which saw increases of 11.20% and 9.37% respectively, while "Medical Equipment" and "Blood Products" lagged with increases of only 0.98% [3][14] Industry Trends - The report highlights significant policy measures from the National Healthcare Security Administration and the National Health Commission aimed at supporting the high-quality development of innovative drugs [5][6] - The introduction of a commercial health insurance innovative drug directory is a key breakthrough, facilitating better pricing and reimbursement mechanisms for high-value drugs [6] - The report emphasizes the importance of the innovative drug industry chain, particularly focusing on platform pharmaceutical companies, clinical CROs, and high-barrier CDMOs [6] Important Industry News - The approval of several innovative drugs, including "ZEGFROVY" by Dize Pharmaceutical and "TQG203" by Zhengda Tianqing, marks significant advancements in the industry [41][42][46] - The report notes that the global number of hemophilia patients is expected to increase by 25% by 2025, highlighting the growing market for innovative treatments [42] - The approval of "Mastrudep" by Innovent Biologics for weight management in adults showcases the expanding therapeutic applications of GLP-1R/GCGR dual agonists [49][50] Investment Recommendations - Continuous attention is recommended for the innovative drug industry chain, particularly for companies that can navigate the new dual directory system and have international expansion capabilities [6] - The report suggests that the recent policy changes and the successful IPO of a biotech company signal a positive outlook for the innovative drug sector [6]

Investment Rating - The report maintains a "Buy" rating for the company [4] Core Viewpoints - Fumetinib at a dosage of 240mg achieved a median progression-free survival (mPFS) of 16 months, significantly outperforming existing therapies [2] - The current first-line treatments for EGFR PACC mutation NSCLC have mPFS ranging from 7.5 to 10 months, indicating Fumetinib's potential as a superior therapy [2] - The global Phase III trial for Fumetinib targeting first-line EGFR PACC mutation NSCLC is expected to enroll its first patient in the second half of 2025, addressing a significant unmet clinical need [3] Financial Projections - The company's projected revenues for 2025, 2026, and 2027 are 45.3 billion, 55.4 billion, and 66.2 billion CNY, respectively, with year-on-year growth rates of 27.4%, 22.1%, and 19.6% [4] - The net profit attributable to the parent company is expected to be 17.7 billion, 20.9 billion, and 25.0 billion CNY for the years 2025, 2026, and 2027, reflecting growth rates of 23.5%, 18.1%, and 19.7% [4] - The company is expected to maintain a relatively low price-to-earnings (PE) ratio compared to its peers, with PE ratios of 25, 21, and 18 for the years 2025, 2026, and 2027 [4] Market Context - The report highlights that approximately 12.5% of all EGFR mutation NSCLC cases are due to PACC mutations, with an annual incidence of 87,000 globally and 54,000 in China, indicating a substantial market opportunity [3]

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index (000683) has shown a strong increase of 1.56% as of July 4, 2025, with notable gains from constituent stocks such as Zhenhua Cell (688520) up 14.55%, Rongchang Bio (688331) up 12.37%, and Shanghai Yizhong (688091) up 8.67% [1] - The Sci-Tech Biopharmaceutical ETF (588250) rose by 1.62%, with a latest price of 1.13 yuan, and has accumulated a 2.88% increase over the past week as of July 3, 2025 [1] - Baili Tianheng announced that its self-developed first-in-class EGFRXHER3 dual antibody ADC (iza-bren) has reached its primary endpoint in a Phase III clinical trial for nasopharyngeal carcinoma, marking it as the first dual antibody ADC to enter Phase III globally [1] Group 2 - Changchun High-tech's IL-1β monoclonal antibody (Fuxin Qibai) has been approved for the acute gout market, which is projected to be worth billions, and is noted for its rapid onset and low recurrence rate compared to existing NSAIDs and steroid therapies [2] - The approval of this product is expected to enhance Changchun High-tech's product portfolio in the adult autoimmune sector and strengthen its competitive position in the pharmaceutical market [2] - The policy to open public data resources in the medical insurance sector for innovative drug development is anticipated to significantly improve the efficiency of innovative drug research and development [2] Group 3 - As of June 30, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index (000683) include Yuying Medical (688271), BeiGene (688235), and Huatai Medical (688617), with these ten stocks accounting for a total of 50.3% of the index [3]

基金研究 | 基金专题报告 基金研究 证券研究报告 2025 年 07 月 04 日 作者 吴先兴 分析师 SAC 执业证书编号：S1110516120001 wuxianxing@tfzq.com 王喆 分析师 SAC 执业证书编号：S1110520060005 wangzhe@tfzq.com 相关报告 1 《金融工程：基金研究-新经济龙头 引擎：华商中证 A500 指数增强基金配 置价值深度解析》 2025-07-02 2 《金融工程：金融工程-哪些行业景 气度在上行？——细分行业景气度跟踪 -20250701》 2025-07-01 3 《金融工程：金融工程-量化择时周 报 ： 突 破 震 荡 上 轨 后 如 何 应 对 ?》 2025-06-29 基金经理海洋所管理的华商量化优质精选基金采用 "量化行业轮动+基本 面验证"框架，通过个股α、产业β及交易保护三维策略获取超额收益。2024 年接管以来年化收益 6.64%，跑赢 50%同类基金。 业绩归因显示基金对电子、汽车、有色金属的超配为基金贡献较高超额收 益，而对非银金融以及家用电器的低配也为组合贡献了一定的行业配置超 额收益。电子、计算机以及通信 ...

Group 1 - The core viewpoint of the news highlights the positive market sentiment in the biopharmaceutical sector driven by supportive government policies and significant milestones in innovative drug approvals [1][2] - The State Medical Insurance Administration and the National Health Commission issued 16 supportive policies for the high-quality development of innovative drugs, covering research, market access, hospital use, and payment [1] - The FDA's accelerated approval of DiZhe Pharmaceutical's EGFR Exon20ins targeted drug, Shuwozhe®, marks it as the first domestically developed innovative drug approved for this indication globally, further boosting market confidence [1] Group 2 - Guosheng Securities points out that the innovative drug sector within the biopharmaceutical industry is characterized by small and mid-cap pipeline blockbuster features, with a diversification trend in pain relief mechanisms [2] - Everbright Securities analyzes that the pharmaceutical industry's policies, driven by both medical insurance and commercial insurance, expand the market space for innovative drugs, with dynamic adjustments to the medical insurance catalog reducing the access cycle for innovative drugs [2] - Both institutions emphasize the policy dividends and clinical value realization in the innovative drug sector, aligning with the performance of innovative drug companies within the Sci-Tech Biopharmaceutical ETF [2]

Core Insights - The establishment of the Sci-Tech Innovation Board (STAR Market) has enabled 20 innovative biopharmaceutical companies to list under the fifth set of listing standards, reshaping China's biopharmaceutical landscape [1] - The China Securities Regulatory Commission (CSRC) has introduced measures to enhance the STAR Market's support for high-growth, unprofitable tech companies, emphasizing the importance of "hard technology" [1][3] - The fifth set of listing standards allows unprofitable innovative companies to raise funds, breaking traditional capital market constraints and facilitating financing for R&D-focused firms [1][2] Industry Developments - Since its inception, the STAR Market has seen 20 innovative biopharmaceutical companies adopt the fifth set of listing standards, with significant fundraising efforts directed towards advanced technologies such as antibody drugs and ADCs [1] - In 2024, these 20 companies collectively achieved revenue of 14.21 billion yuan, a year-on-year increase of 44.17%, with several companies projected to exceed 1 billion yuan in revenue soon [1] - Companies like Dizhe Pharmaceutical have reported substantial revenue growth, with a 294.24% increase to 360 million yuan, driven by innovative drug development [2] Company Performance - Companies such as Junshi Biosciences have successfully raised over 8 billion yuan through the STAR Market, significantly advancing their clinical projects and R&D initiatives [2][3] - Ailis, which listed under the fifth set of standards, achieved commercialization of its core product within 2 years and 5 months, demonstrating the effectiveness of the STAR Market in supporting innovative firms [3] - ShenZhou Cell has transitioned from having no products or revenue at the time of listing to achieving 2.51 billion yuan in revenue, marking a successful turnaround [5] Innovation Ecosystem - The STAR Market has fostered an innovation-driven ecosystem, enhancing the flow of resources and increasing recognition of innovative technologies within the capital market [3][4] - Companies are increasingly focusing their resources on R&D, maintaining high levels of investment intensity, and establishing a virtuous cycle of research and development [6] - The introduction of the STAR Market has led to a fundamental shift in the development logic of listed companies, prioritizing quality over scale and fostering collaborative ecosystems [6]

Group 1 - The "Eight Measures for Deepening the Reform of the Sci-Tech Innovation Board" have been effectively implemented over the past year, with over 30 reform measures launched, covering areas such as issuance underwriting, refinancing, and mergers and acquisitions [1][2] - The introduction of a 3% maximum quotation exclusion ratio for offline subscriptions has led to a more prudent pricing environment, reducing extreme high-price behaviors among investors [1][2] - The "light asset, high R&D" recognition standard has been officially implemented, encouraging companies to increase R&D investment, with 9 companies already disclosing refinancing plans totaling nearly 25 billion [2][3] Group 2 - The merger and acquisition market on the Sci-Tech Innovation Board has seen significant activity, with 110 new transactions announced in the past year, totaling over 140 billion [3][4] - Notable cases include the first stock swap merger following the revised regulations, showcasing the board's increasing marketization and diversification in transaction pricing and valuation mechanisms [3][4] - Companies are increasingly utilizing various financing methods for mergers, including convertible bonds and private placements, with 12 companies introducing state or industrial capital as controlling shareholders [4][5] Group 3 - Suggestions for further reform include attracting more long-term capital, enhancing the financing environment for unprofitable "hard tech" companies, and improving the valuation guidance for long-term R&D firms [4][5] - The Shanghai Stock Exchange aims to strengthen the Sci-Tech Innovation Board's role as a "testbed" for reforms, enhancing the adaptability and inclusiveness of the system to better support technological innovation and new productivity development [5]